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Mucopolysaccharidosis(MPS) are a group of lysosomal storage disorders 
caused by deficiency of alfa-L-idorinidase. MPS is a progressive multisystem 
tissue and organ dysfunction, including cardiac, respiratory, musculoskeletal 
and visceral manifestations.
MPS 1 divided into three clinical phenotype: Hurler, Hurler–Scheie, Scheie 
syndromes.
Infants with severe disease (Hurler syndrome) are usually diagnosed in the 
first year of life. Upper airway obstruction and frequent ear, nose and throat 
infections dominate the clininical picture at early stage and the full clinical 
picture of short stature, hepatosplenomegaly, coarse face, cardiac involvement 
and learning difficulty and manifestation evolves over the 2nd, 3rd years of 
life.
Skeletal involvement (dysostosis multiplex) include enlarged sella turcica, 
broad ribs, tapering of metacarpals and hooke shape vertebrae.
Diagnostic tests
The diagnosis of MPS1 is based on clinical suspicion supported by appropriate 
clinical and radiological examinations followed by urinary examination for 
glycosaminoglican excretion and then specific enzyme assay.
Treatment
Treatment includes haematopoietic stem cell transplantation (HSCT) and 
enzyme replacement therapy (ERT).
ERT (aldurazyme) using recombinant enzymes are approved for patients 
with MPS I. It reduces the number of episodes of sleep apnea, ameliorates 
rate of growth and joint mobility, and reduces organomegaly and urinary 
GAG excretion. ERT is a safer treatment for these disorders, but limited 
by an inability of the enzyme to cross the blood – brain barrier when given 
intravenous
Bone marrow transplantation from related or unrelated donors or cord 
blood transplantation results in significant clinical improvement of somatic 
disease in MPS I. Clinical effects include increased life expectancy, resolution 
or improvement of growth failure, hepatosplenomegaly, joint stiffness, 
facial appearance, obstructive sleep apnea, heart disease, communicating 
hydrocephalus, and hearing loss. Enzyme activity in serum and urinary GAG 
excretion normalize.
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